-
Kitsap Respiratory Illness Report: Week 17 (4/20/2025 – 4/26/2025)
In week ending April 26, local indicators for influenza were low and continued to approach baseline levels, while indicators for COVID-19 and respiratory syncytial virus (RSV) remained minimal. Other Puget Sound counties observed similar trends. Regional laboratory surveillance most frequently detected rhinovirus among clinical respiratory specimens, followed by SARS-CoV-2 (COVID-19). Fewer than 10 emergency department (ED) visits were attributable to…
-
02/01/22 Health Advisory: FDA Provides Full Approval For Spikevax
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Notifiable Conditions, Provider Resources, UncategorizedCOVID-19 Updates for Providers Requested actions Be aware, U.S. Food and Drug Administration (FDA) granted full authorization to Moderna COVID-19 vaccine for people 18 years or older. Evidence shows the vaccine is safe and effective and manufactured with high quality. The vaccine will now be called Spikevax but has the same formulation as emergency use…
-
Health Advisory: COVID-19 Updates to Transferring Residents Between Long-Term Care and other Healthcare Settings
Advisory or Update, COVID-19, Emerging Diseases and Conditions, Health Advisory, Health Alert, News and Alerts, News and Update, Novel CoronavirusActions Requested Be aware, Washington Department of Health updated the Interim Guidance for Transferring Residents between Long-Term Care and other Healthcare Settings to address health care system capacity shortages. The interim guidance, effective January 21, 2022 until February 18, 2022, waives guidance asking facilities to pause admissions with identified healthcare personnel or facility acquired COVID-19…
-
Kitsap Respiratory Illness Report January 9 – January 15, 2022
Click here to access the latest Kitsap Respiratory Illness Report: 1.9.22 – 1.15.22.
-
Kitsap Respiratory Illness Report January 2 – January 8, 2022
Click here to access latest Kitsap Respiratory Illness Report: 1.2.22 – 1.8.22.
-
Health Advisory: CDC updated antiviral guidance
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Health Alert, Immunization, News and Alerts, News and Update, Notifiable Conditions, Novel Coronavirus, Provider Resources, SchoolsActions Requested Be aware, Centers for Disease Control and Prevention (CDC) updated its COVID-19 monoclonal antibody treatment recommendations. Sotrovimab monoclonal antibody formulation retains significant efficacy against Omicron, the dominant circulating variant. Other monoclonal antibody formulations under emergency use authorization (EUA)—bamlanivimab and etesevimab and casirivimab and imdevimab—lack clinical benefit against Omicron and should not be used…
-
01/06/22 Health Advisory: Booster Eligibility Expanded
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Immunizations, News and Alerts, Notifiable Conditions, Provider ResourcesCOVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) endorsed Advisory Committee on Immunization Practices’ (ACIP’s) decision to strongly recommend a single Pfizer COVID-19 vaccine booster dose for people 12–17 years old at least 5 months after their primary series. This expands the age of booster access and strengthens…
-
01/04/22 Health Advisory: CDC updated antiviral guidance
Advisory or Update, COVID-19, Health Advisory, News and Alerts, Notifiable Conditions, Provider ResourcesCOVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) updated its COVID-19 monoclonal antibody treatment recommendations. Sotrovimab monoclonal antibody formulation retains significant efficacy against Omicron, the dominant circulating variant. Other monoclonal antibody formulations under emergency use authorization (EUA)—bamlanivimab and etesevimab and casirivimab and imdevimab—lack clinical benefit against Omicron and…
-
Kitsap Respiratory Illness Report December 19 – December 25, 2021
Click here to access the latest Kitsap Respiratory Illness Report: 12.19.21 – 12.25.21.
-
Health Advisory: COVID-19 Updates for Providers – New I&Q Guidance, FDA grants EUA to Molnupiravir
COVID-19, Emerging Diseases and Conditions, Health Advisory, Health Alert, Infection Control, News and AlertsActions Requested Be aware, Centers for Disease Control and Prevention (CDC) issued new isolation and quarantine (I&Q) guidance for healthcare workers (HCWs). The guidance is complex and varies based on vaccination status, level of exposure and level of crisis in the community. Carefully review the new guidance for details. Following exposure, CDC recommends: Boosted HCWs…
-
Health Advisory: Paxlovid Granted EUA and Testing Before Gathering
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Emerging Diseases and Conditions, Health Advisory, Health Alert, Immunization, Immunizations, Infection Control, News and Alerts, News and Update, Notifiable Conditions, Novel Coronavirus, Prevention, Provider Resources, Schools, Travel, VaccineActions Requested Be aware, Food and Drug Administration (FDA) granted emergency use authorization (EUA) to the first oral antiviral treatment for COVID-19, Pfizer’s Paxlovid. The EUA comes after research showed Paxlovid was nearly 90% effective at preventing hospitalization and death in people 12 years or older at high risk of severe outcomes within 5 days…
-
Health Advisory: Updated J&J Vaccine Recommendations
Requested actions Be aware, on December 16, Centers for Disease Control and Prevention (CDC) recommended mRNA COVID-19 vaccines (Pfizer or Moderna) over Johnson & Johnson (J&J) COVID-19 vaccine for all people 18 years or older. The recommendation is based on the increased risk of thrombosis with thrombocytopenia syndrome (TTS) after getting J&J COVID-19 vaccine. Be…
